Assay Development, FDA Approval and Therapies

Article FDA Thank You The next chapter in the ctDNA story: Still promising, not ready for prime time

Agency IQ

JULY 21, 2023

subsequent superior/inferior supportive care, lifestyle changes, and/or use of additional therapies). That’s why, according to FDA’s Oncology Center of Excellence, the determination of an appropriate endpoint in oncology is based on the specific disease and is highly dependent upon numerous factors.

FDA

FDA Clinical Trials Treatment Trials

Drug Discovery Digest

Article FDA Thank You The next chapter in the ctDNA story: Still promising, not ready for prime time

Webinars

Stay Connected